Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-04-10
2007-04-10
Yaen, Christopher H. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S130100
Reexamination Certificate
active
09570737
ABSTRACT:
Compositions and methods for the therapy and diagnosis of cancer, such as prostate cancer, are disclosed. Compositions may comprise one or more prostate-specific proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a prostate-specific protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and treatment of diseases such as prostate cancer. Diagnostic methods based on detecting a prostate-specific protein, or mRNA encoding such a protein, in a sample are also provided.
REFERENCES:
patent: 6130043 (2000-10-01), Billing-Medel et al.
patent: 6252047 (2001-06-01), Billing-Medel et al.
patent: 6261562 (2001-07-01), Xu et al.
patent: 6620922 (2003-09-01), Xu et al.
patent: 2003/0185830 (2003-10-01), Xu et al.
patent: WO 95/04548 (1995-02-01), None
patent: WO 95/14772 (1995-06-01), None
patent: WO 95/030758 (1995-11-01), None
patent: WO 96/21671 (1996-07-01), None
patent: WO 97/33909 (1997-09-01), None
patent: WO 98/12302 (1998-03-01), None
patent: WO 98/17687 (1998-04-01), None
patent: WO 98/20117 (1998-05-01), None
patent: WO 98/31799 (1998-07-01), None
patent: WO 98/37039 (1998-08-01), None
patent: WO 98/37093 (1998-08-01), None
patent: WO 98/37418 (1998-08-01), None
patent: WO 98/38310 (1998-09-01), None
patent: WO 98/39446 (1998-09-01), None
patent: WO 98/45435 (1998-10-01), None
patent: WO 98/50567 (1998-11-01), None
patent: WO 99/06548 (1999-02-01), None
patent: WO 99/06550 (1999-02-01), None
patent: WO 99/06552 (1999-02-01), None
patent: WO 99/25825 (1999-05-01), None
patent: WO 99/31236 (1999-06-01), None
patent: WO 99/67384 (1999-12-01), None
patent: WO 00/04149 (2000-01-01), None
patent: WO 01/25272 (2001-04-01), None
patent: WO 01/34629 (2001-05-01), None
patent: WO 01/34802 (2001-05-01), None
patent: WO 01/51633 (2001-07-01), None
patent: WO 01/81577 (2001-11-01), None
Gura (Science, v278, 1997, pp. 1041-1042).
Weiner (Seminars Oncology, vol. 26, No. 4, 1999, pp. 41-50).
Dillman (Annals of Internal Medicine, vol. 111, pp. 592-603, 1989).
Jain (Scientific American Jul. 1994, pp. 58-65).
Jansen et al, 1995, Pediatric Res, 37 (6): 681-686.
Alberts et al (Molecular Biology of the Cell, 3rd edition, 1994, p. 465).
Shantz and Pegg (Int J of Biochem and Cell Biol., 1999, vol. 31, pp. 107-122).
McClean and Hill (Eur J of Cancer, 1993, vol. 29A, pp. 2243-2248).
Fu et al (EMBO Journal, 1996, vol. 15, pp. 4392-4401).
Yokota, J et al (Oncogene, 1988, vol. 3, pp. 471-475).
Short et al., “λ ZAP: a bacteriophage λ expression vector within vivoexcision properties,”Nucleic Acids Research 16(15):7583-7600, 1988.
Sjögren, H., “Therapeutic Immunization Against Cancer Antigens Using Genetically Engineered Cells,”Immunotechnology 3: 161-172, 1997.
Smith et al., “Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search,”Science 274(5291), 1371-1374, Nov. 22, 1996.
Theobald, et al., “Targeting p53 as a general tumor antigen,”Proc. Natl. Sci. USA 92(25):11993-11997, Dec. 5, 1995.
Tusnady and Simon, “Principles governing amino acid compositions of integral membrane proteins: application to topology prediction,”J. Mol. Biol. 283(2):489-506, Oct. 23, 1998.
Van Tsai et al., “In vitroimmunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells,”Critical Reviews in Immunology 18:65-75, 1998.
Vasmatzis et al., “Discovery of three genes specifically expressed in human prostate by expressed sequence tag database analysis,”Proc. Natl. Acad. Sci. USA 95(1):300-304, Jan. 6, 1998.
Yee et al., “Isolation of tyrosinase-specific CD8+and CD4+T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus,”The Journal of Immunology 157(9):4079-4086, Nov. 1, 1996.
Zitvogel et al., “Eradication of Established Murine Tumors Using a Novel Cell-Free Vaccine: Dendritic Cell-Derived Exosomes,”Nature Medicine 4(5): 594-600, May 1998.
Lalvani et al., “Rapid effector function in CD8+memory cells,”J. Exp. Med. 186(6):859-865, Sep. 15, 1997.
National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA551449, Sep. 5, 1997.
National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA551759, Aug. 11, 1997.
National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA631143, Oct. 31, 1997.
National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA653016, Nov. 25, 1997.
Nelson et al, Genbank Accession No. NP—004908, Mar. 18, 2000.
Robson et al., “Identification of prostatic adrogen regulated genes using the differential display technique,”Proceeding of the American Association for Cancer Research Meeting 86, 36: p. 266, Abstract No. 1589,1995.
Schena et al., “Parallel human genome analysis; Microarray-based expression monitoring of 1000 genes,”Proc. Natl. Acad. Sci. USA 93(19):10614-10619, Sep. 17, 1996.
Sherman et al., “Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8,”Science 258(5083):815-818, Oct. 30, 1992.
Ezzell, C., “Cancer vaccines: an idea whose time has come?”The Journal of NIH Research 7:46-49, Jan. 1995.
Hara et al., “Characterization of cell phenotype by a novel cDNA library subtraction system: expression of CD8α in a mast cell-derived interleukin-4-depedent cell line,”Blood 84(1):189-199, Jul. 1, 1994.
Harris et al., “Polycystic Kidney Disease 1: identification and analysis of the primary defect,”J. Am. Soc. of Nephrol. 6:1125-1133, 1995.
Hillier et al., Genbank Accession No. AA100799, Dec. 23, 1997.
Hillier et al., Genbank Accession No. R20590, Apr. 18, 1995.
Hudson, T., Genbank Accession No. G22461, May 31, 1996.
Kroger, B. “New serine protease form human prostate, useful for identifying specific inhibitors, antibodies and probes,” Derwent World Patent Index, Accession No. 99-432218, 1999. See also European Patent EP 936 270 A2.
Chu et al., “CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity,”J. Exp. Med. 186(10): 1623-1631, Nov. 17, 1997.
Coleman et al.,Fundamental Immunology, Wm. C. Brown Publishers, Dubuque, Iowa, 1989, pp. 465-466.
Database EMBL Accession No. AA453562, Jun. 11, 1997, Hillier et al., “Homo sapienscDNA clone 788180”.
Derwent Geneseq Database, Accession No. V58522, Dec. 8, 1998.
Derwent Geneseq Database, Accession No. V61287, Jan. 6, 1999.
Duerst and Nees, “Nucleic acid characteristics of late or early passage cells immortalized by papilloma virus-and related polypeptide(s) and antibodies, used for diagnosis and treatment of cervical cancer and assessing potential for progression of cervical lesions,” Derwent World Patent Index, Accession No. 1998-121623, 1998. See also German Patent DE 19649207 C1.
El-Shirbiny, Prostatic Specific Antigen,Advances In Clinical Chemistry 31:99-133, 1994.
Ahn and Kunkel, “The structural and functional diversity of dystrophin,”Nature Genetics 3: 283-291, Apr. 1993.
Alexeyev et al., “Improved antibiotic-resistance gene cassettes and omega elements forEscherichia colivector construction and in vitro deletion/insertion mutagenesis,”Gene 160:63-67, 1995.
Berthon et al., “Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43,”Am. J. Hum. Genet. 62(6):1416-1424, Jun. 1998.
Blok et al., “Isolation of cDNA that are differentially expressed between androgen-dependent and androgen-independent prostate carcinoma cells using differential display PCR,”The Prostate 26:213-224, 1995.
Busselmakers et al.,
Carter Darrick
Day Craig H.
Dillon Davin C.
Fanger Gary R.
Harlocker Susan L.
Corixa Corporation
Seed IP Law Group PLLC
Yaen Christopher H.
LandOfFree
Compositions and methods for the therapy and diagnosis of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the therapy and diagnosis of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the therapy and diagnosis of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3730971